Alex Dahmani has degrees in Genetics, Immunology, and Business. His academic research focused on human T cell activity using an advanced humanized mouse model. Prior to working at Adaptive Biotechnologies, he worked for Columbia Technology Ventures where he helped review and commercialize new technologies invented on campus. He also started a remote patient monitoring company called Quio Technologies. At Adaptive, he works with biotech and pharma partners who use Adaptive’s immune medicine platform to discover and develop novel immunotherapies for infectious disease, autoimmunity, and oncology.
Also Speaking
Michael E. Meyers
Vice Chairman Head of M&A and Strategic Advisory Services • H.C. Wainwright & Co
31 October 2022
Anthony Ting
17 January 2023
Also Speaking
Investor List
Take a look at some of the investors who attended Advanced Therapies Week 2023.
6 January 2023